• Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2021 Financial Results

    Источник: Nasdaq GlobeNewswire / 24 фев 2022 06:00:00   America/New_York

    SEATTLE, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2021.

    Fiscal Year 2021 Highlights

    • In June, completed a business combination transaction with ARYA Sciences Acquisition Corp III and became a publicly traded company, with gross proceeds from this transaction totaling approximately $345.5 million.
    • Announced research collaborations with top tier research partners at both Amgen, and The University of Texas MD Anderson Cancer Center.
    • Announced a strategic partnership with Abcam for the development and supply of reagents for use on the Nautilus platform.
    • Continued to make progress against key internal milestones across a range of platform design and science activities in support of planned platform commercialization by the end of 2023.
    • Shared a manuscript that introduces the theoretical foundation for a fundamentally different approach to proteomics, called Protein Identification by Short-epitope Mapping (PrISM).

    “2021 will be remembered as a pivotal year in Nautilus’ history,” said Sujal Patel, CEO of Nautilus. “It was the year we secured the resources necessary to get us through the development and commercialization phase of our journey, signed a number of exciting research collaboration and reagent development and supply partnerships, and made substantial progress on the scientific development required to see more deeply into the proteome than anyone ever has. As we kick off the year, I am incredibly energized by Nautilus’ purpose to change the course of biomedical research and improve the lives and health of millions of people around the world.”

    Fiscal Year 2021 Financial Results

    Operating expenses were $50.5 million for the year-ended December 31, 2021, a $34.8 million or 221% increase from $15.7 million for the year ended December 31, 2020. The increase in operating expenses was driven primarily by an increase in headcount to support ongoing development of our products as well as the costs associated with being a public company.

    Net loss was $50.3 million for the year-ended December 31, 2021, as compared to a net loss of $15.6 million for the corresponding prior year period.

    Cash, cash equivalents, and investments were $362.1 million as of December 31, 2021.

    Webcast and Conference Call Information

    Nautilus will host a conference call to discuss the fourth quarter and fiscal year 2021 financial results, business developments and outlook before market open on Tuesday, February 24th, 2022 at 5:30 AM Pacific Time / 8:30 AM Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.nautilus.bio.

    About Nautilus Biotechnology, Inc.

    Based in Seattle, Washington, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.

    Special Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements in this press release include, but are not limited to, statements regarding Nautilus’ expectations regarding the company’s business operations, financial performance and results of operations; expectations regarding our collaborations and strategic partnerships, including our expectations with respect to the suitability of the Nautilus product platform to investigate proteins and proteoforms, and the ability of our strategic partnership to accelerate technology development and enhance protein detection; and expectations with respect to the functionality and performance of Nautilus’ product platform, its potential impact on pharmaceutical development and drug discovery. These statements are based on numerous assumptions concerning the development of Nautilus’ products and target markets and involve substantial risks, uncertainties and other factors that may cause actual results to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that could materially affect the accuracy of Nautilus’ assumptions and its ability to achieve the forward-looking statements set forth in this press release include (without limitation) the following: Nautilus’ product platform is not yet commercially available and remains subject to significant scientific and technical development, which is inherently challenging and difficult to predict, particularly with respect to highly novel and complex products such as those being developed by Nautilus. Even if our development efforts are successful, our product platform will require substantial validation of its functionality and utility in life science research. In the course of Nautilus’ scientific and technical development and associated product validation and commercialization, we may experience material delays as a result of unanticipated events. We cannot provide any guarantee or assurance with respect to the outcome of our development, collaboration, and commercialization initiatives or with respect to their associated timelines. For a more detailed description of additional risks and uncertainties facing Nautilus and its development efforts, investors should refer to the information under the caption “Risk Factors” in the Registration Statement on Form S-1 filed with the SEC as well as in our Annual Report on Form 10-K to be filed for the year ended December 31, 2021. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, Nautilus disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

    Disclosure Information

    Nautilus uses filings with the Securities and Exchange Commission, its website (www.nautilus.bio), press releases, public conference calls, public webcasts, and its social media accounts as means of disclosing material non-public information and for complying with Regulation FD. Therefore, Nautilus encourages investors, the media, and others interested in Nautilus to review the information it makes public in these locations, as such information could be deemed to be material information.

    Media Contact
    Thermal for Nautilus Biotechnology
    Kaustuva Das
    press@nautilus.bio

    Investor Contact
    investorrelations@nautilus.bio

    Nautilus Biotechnology, Inc.
    Consolidated Balance Sheets
    As of December 31, 2021 and December 31, 2020 (Unaudited)

    (in thousands)December 31,
    2021
     December 31,
    2020
    Assets   
    Current assets:   
    Cash and cash equivalents$185,619  $36,607 
    Short-term investments 160,110   40,135 
    Prepaid expenses and other current assets 3,493   917 
    Total current assets 349,222   77,659 
    Property and equipment, net 2,483   1,371 
    Operating lease right-of-use assets 29,377   4,842 
    Long-term investments 16,371    
    Other long term assets 997   1,139 
    Total assets$398,450  $85,011 
    Liabilities, Redeemable Convertible Preferred Stock, and Stockholders’ Equity (Deficit)   
    Current liabilities:   
    Accounts payable$1,723  $470 
    Accrued expenses and other liabilities 3,119   1,069 
    Current portion of operating lease liability 970   1,479 
    Total current liabilities 5,812   3,018 
    Operating lease liability, net of current portion 29,062   3,296 
    Total liabilities 34,874   6,314 
    Redeemable convertible preferred stock:   
    Series Seed redeemable convertible preferred stock    5,494 
    Series A redeemable convertible preferred stock    27,067 
    Series B redeemable convertible preferred stock    75,857 
        
    Stockholders’ equity (deficit):   
    Preferred stock     
    Common stock 12   1 
    Additional paid-in capital 444,388   600 
    Accumulated other comprehensive (loss) income (184)  3 
    Accumulated deficit (80,640)  (30,325)
    Total stockholders’ equity (deficit) 363,576   (29,721)
    Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit)$398,450  $85,011 
            

    Nautilus Biotechnology, Inc.
    Consolidated Statements of Operations
    Three Months and Year Ended December 31, 2021 and 2020 (Unaudited)

     Three Months Ended December 31, Year Ended December 31,
    (in thousands, except share and per share amounts) 2021   2020   2021   2020 
    Operating expenses       
    Research and development$9,893  $3,894  $29,352  $12,432 
    General and administrative 6,923   1,426   21,146   3,312 
    Total operating expenses 16,816   5,320   50,498   15,744 
    Other income (expense), net 127   (32)  183   125 
    Net loss$(16,689) $(5,352) $(50,315) $(15,619)
    Net loss per share attributable to common stockholders, basic and diluted$(0.13) $(0.17) $(0.60) $(0.54)
    Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 124,232,794   31,713,646   84,464,081   29,089,778 
                    

    (1) The weighted-average number of shares of Common Stock outstanding prior to the Business Combination have been retroactively restated to reflect the exchange ratio of approximately 3.6281 established in the Business Combination.

    Nautilus Biotechnology, Inc.
    Consolidated Statements of Cash Flows
    Year Ended December 31, 2021 and 2020 (Unaudited)

     Year Ended December 31,
    (in thousands) 2021   2020 
    Cash flows from operating activities   
    Net loss$(50,315) $(15,619)
    Adjustments to reconcile net loss to net cash used in operating activities   
    Stock-based compensation 7,934   369 
    Amortization of operating lease right-of-use assets 1,823   1,636 
    Depreciation 1,019   710 
    Amortization of premiums on securities, net 183   282 
    Loss on disposal of property and equipment 137   13 
    Changes in operating assets and liabilities:   
    Prepaid expenses and other assets (2,750)  (624)
    Accounts payable 1,261   123 
    Accrued expenses and other liabilities 2,255   695 
    Operating lease liability (788)  (1,581)
    Net cash used in operating activities (39,241)  (13,996)
    Cash flows from investing activities   
    Purchases of securities (221,795)  (68,359)
    Proceeds from sale and maturities of securities 85,100   44,001 
    Purchases of property and equipment (2,269)  (921)
    Net cash used in investing activities (138,964)  (25,279)
    Cash flows from financing activities   
    Net proceeds from reverse recapitalization and PIPE financing 335,409    
    Payments of offering costs (8,129)   
    Proceeds from exercise of stock options 167   42 
    Proceeds from issuance of convertible preferred stock, net of issuance costs    75,857 
    Net cash provided by financing activities 327,447   75,899 
    Net increase in cash, cash equivalents and restricted cash 149,242   36,624 
        
    Cash, cash equivalents and restricted cash at beginning of period 37,219   595 
    Cash, cash equivalents and restricted cash at end of period$186,461  $37,219 
            

    Primary Logo

Опубликовать